ExpreS2ion’s joint venture AdaptVac receives SEK 3.6 million grant for vaccine to reduce antibiotic usage in pigs
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture AdaptVac ApS (“AdaptVac”) has been awarded approx. SEK 3.6 million by the Danish Innovation Foundation for its participation in a vaccine project aimed at preventing post-weaning diarrhea (PWD), a major cause of antibiotic use in the swine industry.The project has been awarded a Grand Solutions grant worth DKK 11 million (SEK 15.2 million) in total, of which DKK 5 million (SEK 6.9 million) supports virus-like particle (VLP) platform technology development with DKK 2.6 million (SEK 3.6 million) earmarked to support